Literature DB >> 15821772

Neuropsychological resiliency after treatment for advanced stage neuroblastoma.

S C Carpentieri1, L R Diller.   

Abstract

The purpose of this study was to describe the neuropsychological functioning of survivors of advanced stage neuroblastoma. In all, 16 survivors, diagnosed at a median of 2.8 years, who had received intensive chemotherapy and surgical treatments, were identified; 11 had received myeloablative consolidation therapy, eight with total body irradiation (TBI). All patients were evaluated with a neuropsychological assessment battery at a median age of 8.8 years. Analyses included comparison of the performances of the TBI group vs the no-TBI group; determination of whether the proportion of individuals with impaired or superior performance on each measure exceeded normative expectations; and performance indexes reflecting patterns of performance. Results indicate no significant deleterious impact of TBI and/or presence or absence of myeloablative therapy on neurocognitive and neurobehavioral functioning. For this cohort, resilience to neuropsychological vulnerability was observed, which included the emergence of a profile of full-scale IQ, verbal IQ, and mathematical achievement well above average expectations. We concluded that the results document a lack of neuropsychological morbidity among this cohort of survivors of advanced stage neuroblastoma, regardless of the inclusion of TBI. Moreover, a striking pattern of excellent neurocognitive functioning with intact neurobehavioral functioning was observed.

Entities:  

Mesh:

Year:  2005        PMID: 15821772     DOI: 10.1038/sj.bmt.1704947

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.

Authors:  Daniel J Zheng; Kevin R Krull; Yan Chen; Lisa Diller; Yutaka Yasui; Wendy Leisenring; Pim Brouwers; Rebecca Howell; Jin-Shei Lai; Lyn Balsamo; Kevin C Oeffinger; Leslie L Robison; Gregory T Armstrong; Nina S Kadan-Lottick
Journal:  Cancer       Date:  2018-06-11       Impact factor: 6.860

2.  Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems.

Authors:  L E Cohen; J H Gordon; E Y Popovsky; S Gunawardene; E Duffey-Lind; L E Lehmann; L R Diller
Journal:  Bone Marrow Transplant       Date:  2014-01-20       Impact factor: 5.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.